Psilocybin, LSD et al. – An overview of the 'new’ Psychedelic Assisted Therapies (2 CEUs)
presented by one of the primary researchers in the field:
Thomas D. Meyer Ph.D.
Objectives:
After the presentation, participants will
... be able to discuss what contributed to the almost complete shut down of psychedelic research in the 70's.
... list at least two mental health areas where Psychedelic Assisted Therapy has shown promising positive results.
... be able to name at least two strategies used to provide psychological support in the context of Psychedelic Assisted Therapies.
... know what the terms 'set‘ and 'setting‘ mean when it comes to Psychedelic Assisted Therapy.
When: Friday, July 14th, 2023 from 2:00-4:00 p.m.
Where: Online via Zoom (link will be emailed 2 days before the event)
Cost: BVPA Members Free, Non-Members $55, TPA Members 10% discount at registration with TPA Member Number, Student Non-Members $10.
About our speaker:
Thomas D. Meyer, PhD
Professor, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth)
Director, Psychological Intervention & Research Program for Mood Spectrum Disorders, UT Health Houston
Co-Director, The UTHealth Brain Collection for Research in Psychiatric Disorders
Dr. Meyer, Ph.D., a Licensed Clinical Psychologist with over twenty years of experience conducting research in Germany and the United Kingdom, joined UTHealth in 2014. He has published papers on a variety of topics such as screening for bipolar disorders (BD) and misdiagnoses of or attitudes towards individuals with mood disorders. However, his core interest has always been developing and evaluating psychosocial treatments to improve or maintain mental health. He was the PI of the first published randomized controlled trial (RCT) of Cognitive Behavior Therapy (CBT) for BD in Germany as well as a large study looking at risk factors for mood disorders, and involved as Co-I on several other funded projects; for example, studies evaluating early intervention for recurrent mood disorders, or the ABC study (a cohort study of Bipolar II disorder).
Recently he developed a strong interest in the potential of psychedelic substances for mental health and well-being when he was the lead therapist in an international multi-site Phase II study testing psilocybin in patients with treatment resistant depression. Since then he has explored how mental health professionals feel about psychedelics. While he is currently involved in trials using psilocybin and LSD, he is also the PI of a study looking at the motivation and effects of trying psychedelics recreationally in individuals with bipolar disorder. One of his recent publications is "Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment."
(December 2022, Journal of Affective Disorders 323(6))
